Sniffing out a new COVID defense: early nasal vaccine trial begins
NCT ID NCT07416539
Summary
This is an early-stage study testing a new COVID-19 vaccine given as a nasal spray. Researchers want to see if two slightly different versions of the vaccine are safe and can trigger a good immune response in healthy adults. Participants will get two doses, one month apart, and their health and immune response will be closely monitored for over a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kuopio University Hospital, ENT policlinic
RECRUITINGKuopio, Northern Savonia, 70210, Finland
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.